Clinical trials: Gastrointestinal Stromal Tumour (GIST)
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Gastro-Intestinal Stromal Tumour
Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of…
- Trial name
- NCT02009423
- Testing
- Masitinib
- Volunteers
- 7 people
- Sponsor
- AB Science
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
The primary objectives of the study are: Determine the safety and maximum tolerated dose (MTD) of IPI-504 in GIST and STS patients who have failed prior therapies Recommend a dose for subsequent studies of IPI-504
- Trial name
- NCT00276302
- Testing
- IPI-504
- Where
- 5 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Gastrointestinal Stromal Tumors
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent…
- Trial name
- NCT04282980
- Testing
- DCC-2618
- Where
- 9 sites in China
- Volunteers
- 39 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered…
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Trial name
- NCT02571036
- Testing
- DCC-2618
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 282 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumor
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to imatinib treatment.
- Trial name
- NCT00075218
- Testing
- SU011248
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 361 people
- Sponsor
- Pfizer
Gastrointestinal Neoplasms
A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
This study aims to evaluate the long-term safety and tolerability of velzatinib (GSK6042981) in adults with GIST who have previously received velzatinib in parent study and continue to benefit from the treatment.
- Trial name
- NCT07843641
- Testing
- Velzatinib
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Tumors
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
This is a multicenter, post-marketing, clinical study evaluating the safety and efficacy of postoperative adjuvant therapy with Imatinib Mesylate in high-risk patients after curative resection of newly diagnosed GIST.Patients…
- Trial name
- NCT00171977
- Testing
- Imatinib Mesylate
- Where
- Japan
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Gastrointestinal Stromal Tumors
Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments
To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies
- Trial name
- NCT07618377
- Testing
- DCC-2618
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Gastrointestinal Stromal Tumors (GIST)
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
The mainstay of therapy for GISTs is surgical resection, however, recurrence is almost inevitable in high-risk tumors and secondary surgery or other salvage therapy has yielded poor outcome.
- Trial name
- NCT00633295
- Testing
- AMN107- NILOTINIB
- Where
- 3 sites in Israel
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced gastrointestinal stromal tumor who have exhausted all currently approved standard anti-cancer treatment options.
- Trial name
- NCT02232620
- Testing
- BBI503
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Sumitomo Pharma America, Inc.
Gastrointestinal Stromal Tumors
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
- Trial name
- NCT01689376
- Testing
- Regorafenib (BAY73-4506)
- Sponsor
- Bayer
Gastrointestinal Stromal Tumors, GIST
A Drug-drug Interaction Study of Avapritinib and Midazolam
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST)…
- Conditions
- Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
- Trial name
- NCT04908176
- Testing
- Avapritinib, midazolam
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Blueprint Medicines Corporation
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
The purpose of this expanded access program (EAP) is to provide investigational bezuclastinib so that it can be coadministered with sunitinib to patients with a diagnosis of gastrointestinal stromal tumors (GIST) with no…
- Trial name
- NCT06948955
- Testing
- Bezuclastinib, Sunitinib
- Where
- 26 sites in United States
- Sponsor
- Cogent Biosciences, Inc.
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Advanced Gastrointestinal Stromal Tumor
An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States
This is an observational study in which data already collected from people with advanced gastrointestinal stromal tumors are studied.
- Trial name
- NCT06321055
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Bayer
GIST
Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
Retrospective correlation of clinical outcomes data with mutational status in GIST subjects treated with sunitinib.
- Trial name
- NCT01459757
- Testing
- non-interventional
- Where
- 36 sites in United States, Australia and 14 more
- Volunteers
- 322 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
The study is being conducted to evaluate the efficacy and safety of famitinib in the treatment of advanced gastrointestinal stromal tumour patients after failure of imatinib compared to sunitinib.
- Trial name
- NCT04409223
- Testing
- Famitinib capsules, Sunitinib Capsules
- Where
- China
- Volunteers
- 185 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.